antiplatelet therapy and pci in unstable angina and nstemi giuseppe biondi zoccai divisione di...
TRANSCRIPT
![Page 1: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/1.jpg)
Antiplatelet therapy and PCI in Antiplatelet therapy and PCI in
unstable angina and NSTEMIunstable angina and NSTEMI
Giuseppe Biondi ZoccaiGiuseppe Biondi Zoccai
Divisione di Cardiologia, Università di TorinoDivisione di Cardiologia, Università di Torino
[email protected]@gmail.com
![Page 2: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/2.jpg)
DisclosureDisclosure
• No funding or conflict of interest to declare
![Page 3: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/3.jpg)
TopicsTopics
• Introduction and pathophysiologic
insights
• Antiplatelet regimens
• Triage to invasive management
• State of the art PTCA
![Page 4: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/4.jpg)
TopicsTopics
• Introduction and pathophysiologic
insights
• Antiplatelet regimens
• Triage to invasive management
• State of the art PTCA
![Page 5: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/5.jpg)
Antithrombotictherapy &
(selectively)invasive
management
Stable angina
Unstableangina
Reperfusion(thrombolysis and/or PTCA)
Minutes Hours
DaysWeeks
STEMIUA/NSTEMIAtherothrombosisNew terms
Old terms
Plaque Plaque rupturerupture
Non-Q MI Q-MI
Acute coronary syndromesAcute coronary syndromes
![Page 6: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/6.jpg)
Scope of the problemScope of the problemThrombotic eventsThrombotic events
Myocardial Myocardial ischemiaischemia
BleedingBleeding
Peri-procedural Peri-procedural complicationscomplications
![Page 7: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/7.jpg)
Scope of the problemScope of the problemThrombotic eventsThrombotic events
Myocardial Myocardial ischemiaischemia
BleedingBleeding
Peri-procedural Peri-procedural complicationscomplications
![Page 8: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/8.jpg)
Scope of the problemScope of the problem
![Page 9: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/9.jpg)
Scope of the problem: AMIScope of the problem: AMI
Capewell et al, Heart 2006
![Page 10: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/10.jpg)
Scope of the problem: Scope of the problem: unstable anginaunstable angina
Capewell et al, Heart 2006
![Page 11: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/11.jpg)
Pathways to thrombosisPathways to thrombosis
****
** **Myers, BUMC Proceedings 2005
![Page 12: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/12.jpg)
Multiple vulnerable coronary Multiple vulnerable coronary
plaques in patients with AMIplaques in patients with AMI
Asakura et al, J Am Coll Cardiol 2001
![Page 13: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/13.jpg)
Multiple ruptured coronary Multiple ruptured coronary
plaques in patients with ACSplaques in patients with ACS
![Page 14: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/14.jpg)
Endothelialization of stent strutsEndothelialization of stent struts
Guagliumi et al, Ital Heart J 2003
SES BMS
![Page 15: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/15.jpg)
TopicsTopics
• Introduction and pathophysiologic
insights
• Antiplatelet regimens
• Triage to invasive management
• State of the art PTCA
![Page 16: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/16.jpg)
0.00
0.05
0.10
0.15
0.20
0.25
0 3 6 9 12
Months
Pro
bab
ility
of
de
ath
or
MI Placebo
ASA 75 mg
Risk ratio after 1 year 0.5295% Cl 0.37–0.72 (P=0.0001)
Wallentin et al, JACC 1991
Aspirin in unstable anginaAspirin in unstable angina
![Page 17: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/17.jpg)
3,7
1,7
0
1
2
3
4
Serious bleeding
(%)
ASA+UFH ASA
Theroux et al, NEJM 1988
UF Heparin in NSTEACSUF Heparin in NSTEACS
![Page 18: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/18.jpg)
LMW heparin in NSTEACSLMW heparin in NSTEACS
![Page 19: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/19.jpg)
Cu
mu
lati
ve h
azar
d r
ates
fo
r C
V d
eath
/MI
Days of follow-up
a = median time PCI (10 days)b = 30 days after median time of PCI
0.15
0.10
0.05
0.0
1000
40 100 200 300 400
a b
PlaceboClopidogrelClopidogrel
12.6%
8.8%
1.9% ARR31% RRRP=0.002N=2,658
Mehta et al, Lancet 2001
PCI-CURE SubstudyPCI-CURE Substudy
![Page 20: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/20.jpg)
Cuisset et al, JACC 2006
*P=0.02
N=146
N=146
1-M
on
th
Clopidogrel loading in pts Clopidogrel loading in pts with ACS undergoing PCIwith ACS undergoing PCI
![Page 21: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/21.jpg)
Kastrati et al, JAMA 2006
Benefits of abciximab in ACS patients Benefits of abciximab in ACS patients pretreated with 600 mg clopidogrelpretreated with 600 mg clopidogrel
*Death/MI/urgent TVR
*
600 mg clopidogrel500 mg ASA
>2 h before PCI
![Page 22: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/22.jpg)
13,800 pts
Endpoint: Death/MI/urgentTVR
Bivalirudin in ACS: the ACUITY TrialBivalirudin in ACS: the ACUITY Trial
Stone et al, TCT 2006
![Page 23: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/23.jpg)
ESC guidelinesESC guidelines
![Page 24: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/24.jpg)
2002 ESC guidelines on NSTEACS2002 ESC guidelines on NSTEACS
Bertrand et al, EHJ 2002
![Page 25: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/25.jpg)
Bertrand et al, EHJ 2002
2002 ESC guidelines on NSTEACS2002 ESC guidelines on NSTEACS
![Page 26: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/26.jpg)
Silber et al, EHJ 2005
2005 ESC guidelines on PCI2005 ESC guidelines on PCI
![Page 27: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/27.jpg)
Overwhelming complexity?Overwhelming complexity?
![Page 28: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/28.jpg)
Bertrand et al, EHJ 2002; Silber et al, EHJ 2005
ESC guidelines: a synthesisESC guidelines: a synthesis• ASPIRIN:ASPIRIN: 500 mg oral or 300 mg IV loading dose, followed by 75-100
mg daily lifelong
• CLOPIDOGREL:CLOPIDOGREL: 300 to 600 mg loading dose ASAP, followed by 75 mg daily for 9-12 months
• DIRECT THROMBIN INHIBITORS:DIRECT THROMBIN INHIBITORS: as replacement of UFH or LWM for heparin-induced thrombocytopenia, or in patients at high-risk of bleeding but low risk of procedural ischemic events
• GPIIB/IIIA INHIBITORS:GPIIB/IIIA INHIBITORS: routinely in high-risk patients, provisionally in others (abciximab or eptifibatide in the cath lab if immediate [<2.5 h] angio or provisional use; eptifibatide or tirofiban if early [<48 h] angio)
• LOW MOLECULAR WEIGHT HEPARINLOW MOLECULAR WEIGHT HEPARIN (eg 10 mg/Kg SC enoxaparin twice daily): if invasive strategy is not applicable or deferred
• UNFRACTIONED HEPARIN:UNFRACTIONED HEPARIN: 50-100 IU/Kg IV bolus and additional doses aiming for target ACT (250–350 s without GpIIb/IIIa inhibitors, and 200–250 with them) if immediate or early invasive strategy
![Page 29: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/29.jpg)
TopicsTopics
• Introduction and pathophysiologic
insights
• Antiplatelet regimens
• Triage to invasive management
• State of the art PTCA
![Page 30: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/30.jpg)
Inferiority of invasive therapy?Inferiority of invasive therapy?If PTCA:- routine stenting- bolus + infusion abciximab
Medical Rx:- 300 mg aspirin (then >75 mg)
- 300 mg clopidogrel (then 75 mg)
- 80 mg atorvastatin- 1 mg/Kg enoxaparin
![Page 31: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/31.jpg)
Reconciling current evidenceReconciling current evidence
![Page 32: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/32.jpg)
Reconciling current evidenceReconciling current evidence
Less late PTCA/CABG
Improved (long-term)
survival
But potential increase in peri-procedural
infarctions
Bavry et al, JACC 2006
![Page 33: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/33.jpg)
Invasive vs conservative Rx: impact Invasive vs conservative Rx: impact of stents and antiplatelet treatmentsof stents and antiplatelet treatments
![Page 34: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/34.jpg)
TopicsTopics
• Introduction and pathophysiologic
insights
• Antiplatelet regimens
• Triage to invasive management
• State of the art PTCA
![Page 35: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/35.jpg)
Agostoni et al, JACC 2004
Significantly lower bleedings with radial vs femoral approach PCI
(P=0.05), even selecting studies with ACS patients only (N=291)
Benefits of the radial approachBenefits of the radial approach
![Page 36: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/36.jpg)
Burzotta et al, AJC 2003
Benefits of direct stentingBenefits of direct stenting10 trials with 2576
patients randomized to direct stenting
(DS) vs conventional stenting (CS)
Odds ratio=0.57 (0.35-0.95), P<0.001
![Page 37: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/37.jpg)
Lemos et al, JACC 2003
Safety of sirolimus-eluting Safety of sirolimus-eluting
stents in patients with ACSstents in patients with ACS
![Page 38: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/38.jpg)
Moses et al, JACC 2005
Safety of paclitaxel-eluting Safety of paclitaxel-eluting
stents in patients with ACSstents in patients with ACS
![Page 39: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/39.jpg)
Urban et al, Circ 2006
Predictors of DES thrombosisPredictors of DES thrombosis
![Page 40: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/40.jpg)
Nordmann et al, EHJ 2006
Potential hazards of DESPotential hazards of DES
![Page 41: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/41.jpg)
Take home messagesTake home messages
![Page 42: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/42.jpg)
• Timely triage and administration of standard antithrombotic therapies is pivotal in NSTEACS (ie aspirin, clopidogrel, and heparin [LMW or UFH])
• Glycoprotein IIb/IIIa inhibitors can be administered upstream or directly in the cath lab, and are indicated in high-risk patients
• The role of direct thrombin inhibitors is still to be defined, even if a trade-off between bleeding/peri-procedural MI is likely
• Default invasive or selectively invasive strategies with ad hoc PTCA are both acceptable, as long as the threshold for medical therapy failure remains low
• Choice between DES and BMS is best individualized
Take home messagesTake home messages
![Page 43: Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com](https://reader036.vdocuments.net/reader036/viewer/2022062804/5697bf811a28abf838c85197/html5/thumbnails/43.jpg)
For further slides on these topics please feel free to visit the
metcardio.org website:
http://www.metcardio.org/slides.html